Impaired function of CTLA-4 in the lungs of patients with chronic beryllium disease contributes to persistent inflammation

Journal of Immunology

Volumn 191, Issue 4, 2013, Pages 1648-1656

  Chain, Jennifer L ^a   Martin, Allison K ^a   Mack, Douglas G ^a   Maier, Lisa A ^a,b   Palmer, Brent E ^a   Fontenot, Andrew P ^a,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CHRONIC BERYLLIUM DISEASE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG; LUNG LAVAGE; LYMPHOCYTE PROLIFERATION; MALE; OCCUPATIONAL LUNG DISEASE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL;

ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; BERYLLIOSIS; BRONCHOALVEOLAR LAVAGE FLUID; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CHRONIC DISEASE; CTLA-4 ANTIGEN; GENE EXPRESSION REGULATION; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; INTERLEUKIN-2; LUNG; LYMPHOCYTE ACTIVATION; LYMPHOKINES; MODELS, IMMUNOLOGICAL; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTE SUBSETS; TH1 CELLS;

EID: 84881393414     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300282     Document Type: Article

References (52)

1. Amicosante, M., and A. P. Fontenot. 2006. T cell recognition in chronic beryllium disease. Clin. Immunol. 121: 134-143.
2. Fontenot, A. P., and L. A. Maier. 2005. Genetic susceptibility and immunemediated destruction in beryllium-induced disease. Trends Immunol. 26: 543-549.
3. Sawyer, R. T., and L. A. Maier. 2011. Chronic beryllium disease: an updated model interaction between innate and acquired immunity. Biometals 24: 1-17.
4. Dai, S., G. A. Murphy, F. Crawford, D. G. Mack, M. T. Falta, P. Marrack, J. W. Kappler, and A. P. Fontenot. 2010. Crystal structure of HLA-DP2 and implications for chronic beryllium disease. Proc. Natl. Acad. Sci. USA 107: 7425-7430.
5. + T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. Proc. Natl. Acad. Sci. USA 97: 12717-12722.
6. Falta, M. T., N. A. Bowerman, S. Dai, J. W. Kappler, and A. P. Fontenot. 2010. Linking genetic susceptibility and T cell activation in beryllium-induced disease. Proc. Am. Thorac. Soc. 7: 126-129.
7. + T cells in patients with chronic beryllium disease. J. Clin. Invest. 110: 1473-1482.
8. Tinkle, S. S., L. A. Kittle, B. A. Schumacher, and L. S. Newman. 1997. Beryllium induces IL-2 and IFN-γ in berylliosis. J. Immunol. 158: 518-526.
9. + T cells in patients with beryllium-induced disease. J. Allergy Clin. Immunol. 115: 1036-1042.
10. + T cells. J. Clin. Invest. 112: 776-784.
11. + T cells in chronic beryllium disease. J. Immunol. 180: 2704-2712.
12. Teft, W. A., M. G. Kirchhof, and J. Madrenas. 2006. A molecular perspective of CTLA-4 function. Annu. Rev. Immunol. 24: 65-97.
13. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1: 405-413.
14. Sharpe, A. H., and G. J. Freeman. 2002. The B7-CD28 superfamily. Nat. Rev. Immunol. 2: 116-126.
15. Ishida, Y., Y. Agata, K. Shibahara, and T. Honjo. 1992. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11: 3887-3895.
16. Parry, R. V., J. M. Chemnitz, K. A. Frauwirth, A. R. Lanfranco, I. Braunstein, S. V. Kobayashi, P. S. Linsley, C. B. Thompson, and J. L. Riley. 2005. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25: 9543-9553.
17. Krummel, M. F., and J. P. Allison. 1995. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182: 459-465.
18. Salomon, B., and J. A. Bluestone. 2001. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19: 225-252.
19. Riley, J. L., M. Mao, S. Kobayashi, M. Biery, J. Burchard, G. Cavet, B. P. Gregson, C. H. June, and P. S. Linsley. 2002. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc. Natl. Acad. Sci. USA 99: 11790-11795.
20. Baroja, M. L., and J. Madrenas. 2003. Viewpoint: therapeutic implications of CTLA-4 compartmentalization. Am. J. Transplant. 3: 919-926.
21. Argüello, R. J., M. C. Albareda, M. G. Alvarez, G. Bertocchi, A. H. Armenti, C. Vigliano, P. C. Meckert, R. L. Tarleton, and S. A. Laucella. 2012. Inhibitory receptors are expressed by Trypanosoma cruzi-specific effector T cells and in hearts of subjects with chronic Chagas disease. PLoS ONE 7: e35966.
22. + T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 8: 1246-1254.
23. + T cell function by multiple costimulatory receptors during chronic HIV infection. J. Immunol. 185: 3007-3018.
24. Newman, L. S., K. Kreiss, T. E. King, Jr., S. Seay, and P. A. Campbell. 1989. Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. Am. Rev. Respir. Dis. 139: 1479-1486.
25. Rossman, M. D., J. A. Kern, J. A. Elias, M. R. Cullen, P. E. Epstein, O. P. Preuss, T. N. Markham, and R. P. Daniele. 1988. Proliferative response of bronchoalveolar lymphocytes to beryllium. A test for chronic beryllium disease. Ann. Intern. Med. 108: 687-693.
26. Newman, L. S. 1996. Significance of the blood beryllium lymphocyte proliferation test. Environ. Health Perspect. 104(Suppl. 5): 953-956.
27. Mroz, M. M., K. Kreiss, D. C. Lezotte, P. A. Campbell, and L. S. Newman. 1991. Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. J. Allergy Clin. Immunol. 88: 54-60.
28. Fontenot, A. P., B. L. Kotzin, C. E. Comment, and L. S. Newman. 1998. Expansions of T-cell subsets expressing particular T-cell receptor variable regions in chronic beryllium disease. Am. J. Respir. Cell Mol. Biol. 18: 581-589.
29. Fontenot, A. P., M. T. Falta, B. M. Freed, L. S. Newman, and B. L. Kotzin. 1999. Identification of pathogenic T cells in patients with beryllium-induced lung disease. J. Immunol. 163: 1019-1026.
30. + T cells and their association with HIV-1-induced T cell dysfunction. J. Immunol. 175: 8415-8423.
31. + T cells in blood determines proliferative response. J. Clin. Invest. 115: 2886-2893.
32. Alegre, M. L., P. J. Noel, B. J. Eisfelder, E. Chuang, M. R. Clark, S. L. Reiner, and C. B. Thompson. 1996. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J. Immunol. 157: 4762-4770.
33. Carreno, B. M., F. Bennett, T. A. Chau, V. Ling, D. Luxenberg, J. Jussif, M. L. Baroja, and J. Madrenas. 2000. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J. Immunol. 165: 1352-1356.
34. L induction. J. Immunol. 160: 12-15.
35. Luporsi, E., F. André, F. Spyratos, P. M. Martin, J. Jacquemier, F. Penault-Llorca, N. Tubiana-Mathieu, B. Sigal-Zafrani, L. Arnould, A. Gompel, et al. 2012. Ki- 67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res. Treat. 132: 895-915.
36. Lopez, F., F. Belloc, F. Lacombe, P. Dumain, J. Reiffers, P. Bernard, and M. R. Boisseau. 1991. Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry 12: 42-49.
37. Anderson, D. E., K. D. Bieganowska, A. Bar-Or, E. M. Oliveira, B. Carreno, M. Collins, and D. A. Hafler. 2000. Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population. Nat. Med. 6: 211-214.
38. Palmer, B. E., D. G. Mack, A. K. Martin, L. A. Maier, and A. P. Fontenot. 2007. CD57 expression correlates with alveolitis severity in subjects with berylliuminduced disease. J. Allergy Clin. Immunol. 120: 184-191.
39. Mack, D. G., A. K. Lanham, B. E. Palmer, L. A. Maier, T. H. Watts, and A. P. Fontenot. 2008. 4-1BB enhances proliferation of beryllium-specific T cells in the lung of subjects with chronic beryllium disease. J. Immunol. 181: 4381-4388.
40. Lovett-Racke, A. E., J. L. Trotter, J. Lauber, P. J. Perrin, C. H. June, and M. K. Racke. 1998. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J. Clin. Invest. 101: 725-730.
41. - costimulation-independent T cells in multiple sclerosis. J. Clin. Invest. 108: 1185-1194.
42. Schmidt, D., J. J. Goronzy, and C. M. Weyand. 1996. CD4+ CD72 CD282 T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J. Clin. Invest. 97: 2027-2037.
43. Wang, X. B., C. Y. Zheng, R. Giscombe, and A. K. Lefvert. 2001. Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells. Scand. J. Immunol. 54: 453-458.
44. Jago, C. B., J. Yates, N. O. Câmara, R. I. Lechler, and G. Lombardi. 2004. Differential expression of CTLA-4 among T cell subsets. Clin. Exp. Immunol. 136: 463-471.
45. + T cells is driven by viral replication and associated with T cell dysfunction. J. Immunol. 179: 1979-1987.
46. Sachdeva, M., M. A. Fischl, R. Pahwa, N. Sachdeva, and S. Pahwa. 2010. Immune exhaustion occurs concomitantly with immune activation and decrease in regulatory T cells in viremic chronically HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. 54: 447-454.
47. Lühder, F., P. Höglund, J. P. Allison, C. Benoist, and D. Mathis. 1998. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J. Exp. Med. 187: 427-432.
48. Eggena, M. P., L. S. Walker, V. Nagabhushanam, L. Barron, A. Chodos, and A. K. Abbas. 2004. Cooperative roles of CTLA-4 and regulatory T cells in tolerance to an islet cell antigen. J. Exp. Med. 199: 1725-1730.
49. Karandikar, N. J., C. L. Vanderlugt, T. L. Walunas, S. D. Miller, and J. A. Bluestone. 1996. CTLA-4: a negative regulator of autoimmune disease. J. Exp. Med. 184: 783-788.
50. Hurwitz, A. A., T. J. Sullivan, R. A. Sobel, and J. P. Allison. 2002. Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice. Proc. Natl. Acad. Sci. USA 99: 3013-3017.
51. Hodi, F. S., S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363: 711-723.
52. + T cell subsets and their differentiation. Int. Immunol. 20: 1189-1199.